Table of Contents   Please read below for news-worthy NewsTips and other information including:

-- MedIntelliBase Introduction >> --On Line, On-Time, On Demand, Up-to-Date-- -- Special 40% Discount extended through January 31 --

Cardiovascular MIB MarketTrack Updates --
-- SPIRIT III trial - XIENCE V everolimus-eluting stent -- JUPITER II trial - tacrolimus-eluting Janus Carbostent -- Resten-MP in clinical studies --

Endovascular MIB MarketTrack Updates --
-- Circulase in clinical studies for the treatment of PAD -- Altace for the treatment of PAD -- TROPIC trial - Advicor for the treatment of claudication -- More Information Available at www.MedIntelliBase.com!

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

MedIntelliBase Introduction >> --On Line, On-Time, On Demand, Up-to-Date--

If you are tired of outdated, canned market research reports or databases that do not offer the intelligent insights and analysis you need...then MedIntelliBase is for you. Each month our MIB NewsTips e-newsletters will provide you with a glimpse into our up-to-date, for- subscription, MedIntelliBase MarketTracks - capturing in-depth the most recent market, clinical research and technology intelligence. Our first MarketTracks - the Interventional Medicine Series - cover Cardiovascular, Endovascular, Carotid Artery & Stroke, and Neurovascular Therapeutics.

Take a moment to learn even more about this exciting new way to access up-to-date information and intelligence>>

Visit our webpage at www.MedIntelliBase.com...

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Special 40% Discount extended through February 15

At the request of a few of our clients we also have extended our year- end offer through February 15 to allow you ample budget review time. To introduce you to our innovative products we are offering you a 40% discount on all MedIntelliBase MarketTracks. Just visit our webpage, http://www.MedIntelliBase.com/products.html, to learn more about each of our products, and call me to place this special order. I hope you will take advantage of our limited-time offer.

Our contact information >>

Cardiovascular MIB MarketTrack Updates --

-- SPIRIT III trial - XIENCE V everolimus-eluting stent ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

The SPIRIT III trial - "A Clinical Evaluation of the XIENCE(TM) V Everolimus Eluting Coronary Stent System (CSS) in the Treatment of Subjects with De Novo Native Coronary Artery Lesions" - is currently enrolling patients. The study will compare the XIENCE V stent with the TAXUS Express2 stent. The primary endpoint is in-segment late lumen loss (LLL) at 240 days.

JUPITER II trial - tacrolimus-eluting Janus Carbostent ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

The JUPITER II study is a European multi-center trial designed to evaluate the tacrolimus-eluting Janus Carbostent compared with the bare-metal Tecnic Carbostent. The study's primary endpoint was in- stent and peri-stent LLL at angiographic follow-up.

Resten-MP in clinical studies ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

AVI Biopharma's Resten-MP NeuGene antisense compound (AVI-4126) is developed specifically for systemic delivery. The drug is being evaluated in Phase Ib/II clinical trials for the treatment of restenosis.

Endovascular MIB MarketTrack Updates --

-- Circulase in clinical studies for the treatment of PAD ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Circulase, a prodrug of prostaglandin E(1) within lipid microspheres, is being developed as a therapy for patients with severe PAD. The first controlled trial was initiated in May 1997 with improvements in walking distance and quality of life observed. A Phase III study is currently underway evaluating the effect of Circulase in patients undergoing peripheral revascularization.

Altace for the treatment of PAD ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

The ACE inhibitor known as Altace, or ramipril generically, was evaluated in a study to demonstrate that the drug can improve clinical symptoms in patients with peripheral artery disease. The study's primary endpoints were time to onset of claudication, total exercise time, and walking ability.

TROPIC trial - Advicor for the treatment of claudication ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

The TROPIC trial is designed to evaluate the safety and efficacy of Advicor, Niacin ER plus Lovastatin, in patients with intermittent claudication (IC). Percent change in peak walk time is the study's primary endpoint. As of December 2005 this trial had not been completed.

More Information Available at www.MedIntelliBase.com! ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

You can find more in-depth information about the summaries noted above and many other technologies and clinical studies we have been tracking over the years in our MedIntelliBase MarketTracks >> visit our website at www.MedIntelliBase.com

We will be pleased to help you access the critical intelligence you need to make informed product development and business investment decisions.

Contact us if you need more information...

You can find other related services at our sister division's website at The Next Phase® Consultancy's Home Page.

FYI:

1. MedIntelliBase NewsTips is free and you are welcome to continue receiving it as long as you wish. If at any time you wish to cancel just click the Safe Unsubscribe link below.
2. We will not share your name and e-mail address with anyone.
3. Feel free to share or reproduce the information in this MedIntelliBase NewsTips e-newsletter (in whole or part) as long as proper mention and copyright notice is given to MedIntelliBase and The Next Phase Publishing, Inc.
4. If you are not the original recipient of this newsletter and would like to receive future issues, just click the Forward link below or drop me a line.

We also publish a free monthly e-newsletter on device discovery, definition and development as well as related customer needs analysis, market research, and business development issues called NextTip™ Insight. To subscribe send an email to one of us with "Subscribe to NextTip Insight" in the subject line. You can find past issues at www.TheNextPhase.com/consultancy/pub_newsletter.html.

Editor: Vicky Hunsicker Sanko
The Next Phase Publishing, Inc.